Streetbeat News

AGYTF

Allergy Therapeutics Plc

http://www.allergytherapeutics.com/

CEO

Manuel Llobet

Industry

Medicinal and Botanical Manufacturing

Open

0.02

Mkt cap

248M

Volume

High

0.05

P/E Ratio

-5.20

52-wk high

0.06

Low

0.02

Div yield

N/A

52-wk low

0.01

Allergy Therapeutics PLC is overcoming past manufacturing setbacks and is now focusing on innovation to redefine its business strategy.

Portfolio Pulse from

December 19, 2024 | 1:00 pm

Allergy Therapeutics has released promising interim results from its phase I/IIa VLP Peanut PROTECT trial, which uses a nanoparticle-based treatment to address peanut allergies. The early data suggests that the treatment could reduce sensitivity and allergic reactions to peanuts.

Portfolio Pulse from

December 04, 2024 | 8:30 am

Allergy Therapeutics has started a phase III trial to test the safety and effectiveness of its Grass MATA MPL allergy treatment in children, marking the first industry trial of its kind for pediatric patients with grass pollen-induced allergic rhinitis.

Portfolio Pulse from

November 27, 2024 | 8:00 am

Allergy Therapeutics has applied for regulatory approval for its new grass allergy immunotherapy, marking a significant milestone. The application was submitted to Germany's Paul Ehrlich Institut and includes positive phase III clinical trial results.

Portfolio Pulse from

November 25, 2024 | 7:45 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.